Clinical Trial Update: A Dose-Response Safety Study of ENX-102 in Patients With GAD [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 dose-response safety study of ENX-102 in patients with Generalized Anxiety Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• ENX-102

Snippet

Sponsor: Engrail Therapeutics INC | Conditions: General Anxiety Disorder | Phase 2 | Status: COMPLETED